Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of isochlorogenic acid compound and different combinations in hepatitis treatment

A technology of isochlorogenic acid and compounds, applied in the application field of isochlorogenic acid compounds and different combinations in the treatment of hepatitis, to achieve the effect of strong anti-hepatitis B virus, inhibition of replication, and simple and easy extraction process

Inactive Publication Date: 2009-03-11
伍义行
View PDF0 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Literature search shows that there is no research report on the anti-hepatitis B effect of these three phenolic components at home and abroad

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of isochlorogenic acid compound and different combinations in hepatitis treatment
  • Use of isochlorogenic acid compound and different combinations in hepatitis treatment
  • Use of isochlorogenic acid compound and different combinations in hepatitis treatment

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] The isochlorogenic acid composition can secrete HBsAg (hepatitis B virus surface antigen), HBeAg (hepatitis B virus E antigen) and HBV-DNA (hepatitis B virus) to transfect HBV (hepatitis B virus) gene HepG2. Inhibition of the viral replication number of the virus).

[0039] Determination of the inhibitory effect of the sample on the growth of HepG2.2.15 cells: the cells were digested with trypsin-EDTA and diluted to 1×10 5 / mL, added to a 96-well cell culture plate, 100uL per well, placed in CO 2 cultured in an incubator. After 24 hours of inoculation, discard the medium, add the sample diluted with the medium, 200ul per well, add 3 wells for each concentration, add 5mg / ml MTT to the cell culture wells after 72 hours of culture, 10ul per well, and place at 37°C After incubation for 3 hours, 150ul of DMSO was added to completely dissolve the formazan, and a microplate reader was used for colorimetry at a wavelength of 570nm. Calculate the median toxic concentration of...

Embodiment 2

[0045] Example 2 Effect of isochlorogenic acid composition on liver cell injury induced by D-GalN (galactosamine)

[0046] Human normal liver cell line HL-7702, placed at 37°C in CO 2 Culture in an incubator; after the hepatocytes adhered to the wall, replace the culture medium, add 20mmol / l D-GalN, and act for 8h; then discard the culture medium, and add 200μl of different concentrations of the test drug solution, each concentration was set at 6 Repeat wells, set solvent and positive control at the same time; continue to culture for 48h, add 10μl MTT (5mg / ml) to each well, act for 4h, aspirate and discard the supernatant, add 150μl DMSO, shake and mix well; The instrument measures the A value. Protection evaluation: calculation of protection rate (%) and proliferation index.

[0047]

[0048] Note 2: Proliferation index = sample group (A) / injury group (A)

[0049] Table 2 Effect of isochlorogenic acid composition on D-GalN-induced normal human liver cell damage

[0050...

Embodiment 3

[0053] Example 3 Protective effect of isochlorogenic acid composition on D-GalN-induced acute liver injury model in mice

[0054] Materials: 20-25g male ICR mice were randomly divided into groups according to body weight, 10 mice in each group. A normal control group, an injury control group, a positive control group and high, medium and low dose groups of the test drug were set up. Animals in the drug group were given prophylactic administration once a day for 7 consecutive days. The normal control group and the injury control group were given an equal volume of solvent, and the positive control group was given 50 mg / kg of silymarin. One hour after the last administration, animals in each group except the normal group were injected with 650 mg / kg galactosamine (D-GalN) intraperitoneally to cause toxicity. 24 hours after the last administration, the serum was separated to measure AST and ALT. At the same time, liver tissue was taken for making pathological sections.

[005...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the application of a compound to treating hepatitis and aims at providing an isochlorogenic acid compound which has stronger effects of anti-HBV, anti-inflammation and liver protection, and has wide and rich sources, and simple and convenient extraction process. The technical proposal is as follows: the isochlorogenic acid compound is made from one or more than one of isochlorogenic acid A, isochlorogenic acid B and isochlorogenic acid C according to any mixture ratio; in addition, the technical proposal further comprises the application of the compound to preparing drugs for resisting hepatitis B virus, and resisting inflammation and protecting liver.

Description

technical field [0001] The invention relates to the application of a compound in the treatment of hepatitis, especially the application of isochlorogenic acid compounds and different combinations in the treatment of hepatitis. Background technique [0002] Hepatitis is a general term for inflammatory diseases of the liver. According to the etiology, it can be divided into viral, alcoholic, drug-induced and autoimmune hepatitis. Viral hepatitis is the most common, of which hepatitis B is the main one, and hepatitis C next. According to statistics, there are about 300 million hepatitis B virus carriers in the world at present, and the infection rate of hepatitis C in some special populations is as high as 70%. China is one of the countries with a high incidence of liver disease, and about 300,000 people die of liver disease every year. At present, there are about 100 million people infected with hepatitis B in my country, and the number of virus carriers is as high as 130 mi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/216A61P1/16A61P31/12
Inventor 伍义行郝冰洁张晓梦
Owner 伍义行
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com